首页> 外文期刊>Journal of human hypertension >Safety and efficacy of oral anticoagulation therapy in Chinese patients with concomitant atrial fibrillation and hypertension.
【24h】

Safety and efficacy of oral anticoagulation therapy in Chinese patients with concomitant atrial fibrillation and hypertension.

机译:中国房颤伴高血压患者口服抗凝治疗的安全性和有效性。

获取原文
获取原文并翻译 | 示例
           

摘要

Limited evidence is available on the safety and efficacy of anticoagulants in non-valvular atrial fibrillation (AF) patients with concomitant hypertension. We investigated the safety and efficacy of 476 consecutive anticoagulated Chinese outpatients with non-valvular AF and hypertension. Occurrence of ischaemic stroke and major bleeding, and international normalized ratio (INR) values during these events were recorded. There was no significant difference in anticoagulation control between patients with or without hypertension. INR-specific incidence rates of the events were calculated, which showed no excessive risk for ischaemic stroke (2.5 vs 1.6% per year, P=0.22) or major bleeding (3.9 vs 3.2% per year, P=0.29) in non-valvular AF patients with or without hypertension. In multivariate analysis, congestive heart failure, smoking and high CHADS2 score were independent predictors for ischaemic stroke, whereas use of antiplatelet agents was an independent predictor for bleeding. It can be noted that hypertension was not associated with ischaemic stroke or major bleeding. Hypertensive patients who achieved target blood pressure control (<130/80 mm Hg) had a lower ischaemic stroke (0.9 vs 3.1% per year, P=0.01), but similar bleeding risk compared with those not achieving target blood pressure. Our findings demonstrate the effects of hypertension on the outcomes of warfarin therapy; further investigation is needed to clarify whether more aggressive antihypertensive therapy could result in better outcomes in hypertensive patients with non-valvular AF.
机译:关于抗凝剂在非瓣膜性房颤(AF)伴发高血压中的安全性和有效性方面的证据有限。我们调查了476例连续的非瓣膜性房颤和高血压的中国抗凝门诊患者的安全性和有效性。记录这些事件期间缺血性中风和大出血的发生率,以及国际标准化比率(INR)值。有或没有高血压的患者在抗凝控制方面无显着差异。计算出事件的INR特异性发生率,在非瓣膜中没有显示出缺血性中风的过多风险(每年2.5 vs 1.6%,P = 0.22)或大出血(每年3.9 vs 3.2%,P = 0.29) AF患者有无高血压。在多变量分析中,充血性心力衰竭,吸烟和CHADS2高分是缺血性卒中的独立预测因子,而抗血小板药物的使用是出血的独立预测因子。可以注意到,高血压与缺血性中风或大出血无关。达到目标血压控制(<130/80 mm Hg)的高血压患者缺血性卒中发生率较低(每年0.9%vs 3.1%,P = 0.01),但与未达到目标血压的患者相比,出血风险相似。我们的发现证明了高血压对华法林治疗效果的影响。有必要进一步调查,以阐明在非瓣膜性房颤的高血压患者中,更积极的抗高血压治疗是否可以导致更好的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号